Non-contrast transcatheter aortic valve implantation for patients with aortic stenosis and chronic kidney disease: a pilot study
Carregando...
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Citação
FRONTIERS IN CARDIOVASCULAR MEDICINE, v.10, article ID 1175600, 8p, 2023
Resumo
BackgroundAcute kidney injury (AKI) is frequently observed after transcatheter aortic valve implantation (TAVI). Of note, it is associated with a threefold increase in all-cause and cardiac death. We propose a new non-contrast strategy for evaluating and performing the TAVI procedure that can be especially valuable for patients with aortic stenosis (AS) and chronic kidney disease (CKD) to prevent AKI. MethodsPatients with severe symptomatic AS and CKD stage & GE;3a were evaluated for TAVI using four non-contrast imaging modalities for procedural planning: transesophageal echocardiogram (TEE), cardiac magnetic resonance, multidetector computed tomography (MDCT), and aortoiliac CO2 angiography. Patients underwent transfemoral (TF) TAVI using the self-expandable Evolut R/Pro, and the procedures were guided by fluoroscopy and TEE. Contrast MDCT and contrast injection at certain checkpoints during the procedure were used in a blinded fashion to guarantee patient safety. ResultsA total of 25 patients underwent TF-TAVI with the zero-contrast technique. The mean age was 79.9 & PLUSMN; 6.1 years, 72% in NYHA class III/IV, with a mean STS-PROM of 3.0% & PLUSMN; 1.5%, and creatinine clearance of 49 & PLUSMN; 7 ml/min. The self-expandable Evolut R and Pro were implanted in 80% and 20% of patients, respectively. In 36% of the cases, the transcatheter heart valve (THV) chosen was one size larger than the one by contrast MDCT, but none of these cases presented adverse events. Device success and the combined safety endpoint (at 30 days) both achieved 92%. Pacemaker implantation was needed in 17%. ConclusionThis pilot study demonstrated that the zero-contrast technique for procedural planning and THV implantation was feasible and safe and might become the preferable strategy for a significant population of CKD patients undergoing TAVR. Future studies with a larger number of patients are still needed to confirm such interesting findings.
Palavras-chave
transcatheter aortic valve replacement, aortic stenosis, renal failure, zero contrast, renal insufficiency
Referências
- Cho Kyung Jae, 2015, Vasc Specialist Int, V31, P67, DOI 10.5758/vsi.2015.31.3.67
- Coca SG, 2009, AM J KIDNEY DIS, V53, P961, DOI 10.1053/j.ajkd.2008.11.034
- Codner P, 2015, AM J CARDIOL, V116, P1391, DOI 10.1016/j.amjcard.2015.08.004
- de Brito FS, 2015, CATHETER CARDIO INTE, V85, pE153, DOI 10.1002/ccd.25778
- Elhmidi Y, 2014, ARCH CARDIOVASC DIS, V107, P133, DOI 10.1016/j.acvd.2014.01.002
- Gargiulo G, 2015, CATHETER CARDIO INTE, V86, P518, DOI 10.1002/ccd.25867
- Gebauer K, 2012, INT J NEPHROL, V2012, DOI 10.1155/2012/483748
- Hahn RT, 2018, J AM SOC ECHOCARDIOG, V31, P405, DOI 10.1016/j.echo.2017.10.022
- Hibino M, 2023, AM J CARDIOL, V190, P122, DOI 10.1016/j.amjcard.2022.12.018
- Kappetein AP, 2013, J THORAC CARDIOV SUR, V145, P6, DOI 10.1016/j.jtcvs.2012.09.002
- Najjar M, 2015, EXPERT REV CARDIOVAS, V13, P301, DOI 10.1586/14779072.2015.1002467
- Nunes ACB, 2019, REV ESP CARDIOL, V72, P21, DOI [10.1016/j.rec.2017.11.024, 10.1016/j.recesp.2017.11.018]
- Pascual I, 2022, JACC-CARDIOVASC INTE, V15, P150, DOI 10.1016/j.jcin.2021.10.002
- Popma JJ, 2019, NEW ENGL J MED, V380, P1706, DOI 10.1056/NEJMoa1816885
- Reardon MJ, 2017, NEW ENGL J MED, V376, P1321, DOI 10.1056/NEJMoa1700456
- Rosa VEE, 2021, CARDIORENAL MED, V11, P166, DOI 10.1159/000517058